Truist Securities Rates Viridian Therapeutics (VRDN) buy
Truist Securities maintains its buy rating on VRDN with a $38 price target, a 102.24% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $38 price target on June 30, 2026.
Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).
VRDN
Viridian Therapeutics, Inc.
Key Points
- Truist Securities reiterated its buy rating on VRDN with a $38 price target on June 30, 2026.
- Truist Securities's $38 price target implies 102.24% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- VRDN shares traded around $18.79 on Tuesday.
- FMR LLC, BlackRock, and Bellevue Group AG increased their positions in VRDN.
Get $VRDN trade alerts by text
We text you when insiders, Congress or big funds trade $VRDN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures
Truist Securities has reaffirmed its buy rating on VRDN, setting a price target of $38. This reiteration, announced on June 30, 2026, reflects continued confidence in the stock's potential.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in VRDN
Several institutional investors have been active in VRDN recently. FMR LLC increased its holdings by 994,921 shares, resulting in a total of 15,379,377 shares valued at about $300.82 million, marking a 6.9% increase. BlackRock, Inc. boosted its position by 1,399,552 shares to 7,831,475 shares, worth approximately $153.18 million, a 21.8% rise. Bellevue Group AG added 2,367,617 shares, bringing its total to 6,726,144 shares valued at $131.56 million, reflecting a 54.3% increase. State Street Corp grew its stake by 1,206,325 shares, ending with 4,672,885 shares valued at $91.40 million, a 34.8% increase. Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.51 million.
Viridian Therapeutics, Inc. Stock Down 14.6%
On Tuesday, VRDN shares traded around $18.79. The stock has seen significant interest from institutional investors, evidenced by recent peer activity. This indicates a robust interest in the company's potential growth.
$VRDN price target
Viridian Therapeutics, Inc. daily closes and this analyst's $38 target. Not advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Insider activity at VRDN has been notable. Fairmount Funds Management LLC acquired 1,176,470 shares at an average price of $17 on May 11, 2026. Additionally, several executives, including Chief Legal Officer Jennifer Tousignant, Chief Operating Officer Thomas Beetham, Chief Financial Officer Seth Harmon, and President and CEO Stephen Mahoney, sold shares on March 3, 2026, at an average price of $30.19.
Analysts Set New Price Targets
On June 30, 2026, Truist Securities maintained its buy rating on VRDN with a $38 price target. Wedbush also maintained a buy rating, setting a target of $43. Needham kept its buy rating with a $34 target. On June 29, 2026, Wells Fargo upgraded the stock to a buy with a $31 target. The consensus among analysts is a buy rating, with a mean target price reflecting confidence in VRDN's prospects.
Bottom Line
VRDN has caught the attention of analysts and institutional investors alike, with Truist Securities and others maintaining optimistic views. While the stock currently trades below analyst targets, the reiterated buy ratings suggest potential upside. Investors should note that these assessments are based on past performance and do not necessarily predict future outcomes.
Related Filing Alerts
Source: Truist Securities's rating change on $VRDN (Jun 30, 2026). Written by software, not financial advice. How we make alerts